1. A pharmaceutical composition, comprising:
a) a soluble neutral active human hyaluronidase glycoprotein (sHASEGP), wherein:
the hyaluronidase glycoprotein is active at neutral pH and contains at least one sugar moiety that is covalently attached to an asparagine (N) residue of the hyaluronidase polypeptide;
the hyaluronidase polypeptide does not comprise the complete sequence of amino acids set forth in SEQ ID NO:1; and
the hyaluronidase polypeptide consists of:
(i) a contiguous sequence of amino acid residues contained within SEQ ID NO:1 that includes at least amino acids 36-464 of SEQ ID NO:1, wherein the polypeptide is truncated within the C-terminus of SEQ ID NO:1 at a C-terminal amino acid residue selected from among 477, 478, 479, 480, 481, 482, 483 and 494 of SEQ ID NO:1; or
(ii) a sequence of amino acid residues that has at least 95% amino acid sequence identity with a sequence of amino acids set forth in (i); and
b) immune globulins.
2. The pharmaceutical composition of claim 1, wherein the hyaluronidase glycoprotein has a C-terminal amino acid residue selected from among 477, 478, 479, 480, 481, 482 and 483 of SEQ ID NO:1.
3. The pharmaceutical composition of claim 1, wherein:
(i) the hyaluronidase glycoprotein consists of the sequence of amino acids set forth as amino acids 36-477, 36-478, 36-479, 36-480, 36-481, 36-482, or 36-483 of SEQ ID NO:1; or
(ii) the hyaluronidase glycoprotein contains amino acid substitutions in the sequence of amino acids set forth as amino acids 36-477, 36-478, 36-479, 36-480, 36-481, 36-482, or 36-483 of SEQ ID NO:1, whereby the amino acid-substituted hyaluronidase glycoprotein consists of a sequence of amino acids that has at least 95% amino acid sequence identity with the sequence of amino acids set forth as amino acids 36-477, 36-478, 36-479, 36-480, 36-481, 36-482, or 36-483 of SEQ ID NO:1.
4. The pharmaceutical composition of claim 1 that comprises a hyaluronidase glycoprotein that has a C-terminal amino acid residue selected from among 479, 480, 481 and 482.
5. The pharmaceutical composition of claim 3, wherein the hyaluronidase glycoprotein contains amino acid substitutions in the sequence of amino acids set forth as amino acids 36-477, 36-478, 36-479, 36-480, 36-481, 36-482, or 36-483 of SEQ ID NO:1, whereby the amino acid-substituted hyaluronidase glycoprotein consists of a sequence of amino acids that has at least 97% amino acid sequence identity with the sequence of amino acids set forth as amino acids 36-477, 36-478, 36-479, 36-480, 36-481, 36-482, or 36-483 of SEQ ID NO:1.
6. The pharmaceutical composition of claim 1, wherein the hyaluronidase polypeptide consists of a sequence of amino acids that has at least 98% sequence identity with residues 36-483 of SEQ ID NO:1.
7. The pharmaceutical composition of claim 1, wherein the hyaluronidase glycoprotein is expressed and secreted from mammalian cells.
8. The pharmaceutical composition of claim 7, wherein the mammalian cells are Chinese Hamster Ovary (CHO) cells.
9. The pharmaceutical composition of claim 1, wherein the hyaluronidase glycoprotein is modified with a polymer.
10. The pharmaceutical composition of claim 9, wherein the polymer is PEG or dextran.
11. The pharmaceutical composition of claim 1 that is formulated for subcutaneous administration.
12. The pharmaceutical composition of claim 1 that is formulated for intravenous administration.
13. A combination, comprising:
a) a first composition comprising a soluble neutral active human hyaluronidase glycoprotein (sHASEGP), wherein:
the hyaluronidase glycoprotein is active at neutral pH and contains at least one sugar moiety that is covalently attached to an asparagine (N) residue of the hyaluronidase polypeptide;
the hyaluronidase polypeptide does not comprise the complete sequence of amino acids set forth in SEQ ID NO:1; and
the hyaluronidase polypeptide consists of:
(i) a contiguous sequence of amino acid residues contained within SEQ ID NO:1 that includes at least amino acids 36-464 of SEQ ID NO:1, wherein the polypeptide is truncated within the C-terminus of SEQ ID NO:1 at a C-terminal amino acid residue selected from among 477, 478, 479, 480, 481, 482, 483 and 494 of SEQ ID NO:1; or
(ii) a sequence of amino acid residues that has at least 95% amino acid sequence identity with a sequence of amino acids set forth in (i); and
b) a second composition comprising immune globulins.
14. The combination of claim 13, wherein the hyaluronidase glycoprotein has a C-terminal amino acid residue selected from among 477, 478, 479, 480, 481, 482 and 483 of SEQ ID NO:1.
15. The combination of claim 13, wherein:
(i) the hyaluronidase glycoprotein consists of the sequence of amino acids set forth as amino acids 36-477, 36-478, 36-479, 36-480, 36-481, 36-482, or 36-483 of SEQ ID NO:1; or
(ii) the hyaluronidase glycoprotein contains amino acid substitutions in the sequence of amino acids set forth as amino acids 36-477, 36-478, 36-479, 36-480, 36-481, 36-482, or 36-483 of SEQ ID NO:1, whereby the amino acid-substituted hyaluronidase glycoprotein consists of a sequence of amino acids that has at least 95% amino acid sequence identity with the sequence of amino acids set forth as amino acids 36-477, 36-478, 36-479, 36-480, 36-481, 36-482, or 36-483 of SEQ ID NO:1.
16. The combination of claim 13, wherein the hyaluronidase glycoprotein has a C-terminal amino acid residue selected from among 477, 478, 479, 480, 481, 482 and 483 of SEQ ID NO:1.
17. The combination of claim 13, wherein the hyaluronidase glycoprotein contains amino acid substitutions in the sequence of amino acids set forth as amino acids 36-477, 36-478, 36-479, 36-480, 36-481, 36-482, or 36-483 of SEQ ID NO:1, whereby the amino acid-substituted hyaluronidase glycoprotein consists of a sequence of amino acids that has at least 95% amino acid sequence identity with the sequence of amino acids set forth as amino acids 36-477, 36-478, 36-479, 36-480, 36-481, 36-482, or 36-483 of SEQ ID NO:1.
18. The combination of claim 13, wherein the hyaluronidase glycoprotein contains amino acid substitutions in the sequence of amino acids set forth as amino acids 36-477, 36-478, 36-479, 36-480, 36-481, 36-482, or 36-483 of SEQ ID NO:1, whereby the amino acid-substituted hyaluronidase glycoprotein consists of a sequence of amino acids that has at least 97% amino acid sequence identity with the sequence of amino acids set forth as amino acids 36-477, 36-478, 36-479, 36-480, 36-481, 36-482, or 36-483 of SEQ ID NO:1.
19. The combination of claim 13, wherein the hyaluronidase polypeptide consists of a sequence of amino acids that has at least 98% sequence identity with residues 36-483 of SEQ ID NO:1.
20. The combination of claim 13, wherein the hyaluronidase glycoprotein is expressed and secreted from mammalian cells.
21. The combination of claim 20, wherein the mammalian cells are Chinese Hamster Ovary (CHO) cells.
22. The combination of claim 13, wherein the hyaluronidase glycoprotein is modified with a polymer.
23. The combination of claim 22, wherein the polymer is PEG or dextran.
24. The combination of claim 13, wherein the first and second compositions are formulated for subcutaneous administration.
25. The composition of claim 1, wherein the immune globulin is selected from among cytomegalovirus immune globulin, hepatitis B immune globulin, immune globulin intramuscular, immune globulin intravenous, rabies immune globulin, respiratory syncytial virus immune globulin, immune globulins, tetanus immune globulin and varicella-zoster immune globulin.
26. The composition of claim 1, wherein the immune globulin comprises human immune globulins (human IG).
27. The combination of claim 13, wherein the immune globulin is selected from among cytomegalovirus immune globulin, hepatitis B immune globulin, immune globulin intramuscular, immune globulin intravenous, rabies immune globulin, respiratory syncytial virus immune globulin, immune globulins, tetanus immune globulin and varicella-zoster immune globulin.
28. The combination of claim 13 wherein the immune globulin comprises human immune globulins (human IG).
29. A method of treatment of a subject, comprising administering a composition of claim 1.
30. A method of treatment of a subject, comprising administering a composition of claim 26.
31. A method of treatment of a subject, comprising administering a combination of claim 13.
32. A method of treatment of a subject, comprising administering a combination of claim 28.
The claims below are in addition to those above.
All refrences to claim(s) which appear below refer to the numbering after this setence.
1. A data transferring method, wherein,
a data transmitting wireless terminal validates an Acknowledgement (Ack) request data provided within a wireless data frame and transmits the wireless data frame;
a data receiving wireless terminal determines whether or not a frame identifier data indicating a sequence of each Ack request data provided in the wireless data frame received from the data transmitting wireless terminal is an expected one and whether or not a present Ack request data receiving interval is longer than a last Ack request data receiving interval, and decreases a redundant predetermined number of transmission frequency of each Ack data in response to each Ack request data in case that the frame identifier data is found to be an expected one and the present Ack request data receiving interval is found to be longer than the last Ack request data receiving interval, or increases the redundant predetermined number of transmission frequency either in case that the frame identifier data is found to be not an expected one or in case that the present Ack request data receiving interval is found to be not longer than the last Ack request data receiving interval while updating the Ack request data receiving interval to the present interval in either case; and
the data transmitting wireless terminal extends or shortens a cycle for transmitting the Ack request data respectively depending on whether or not the Ack data in response to the Ack request data has been received within a fixed time during the cycle.
2. The data transferring method as claimed in claim 1, wherein only when the Ack request data is valid the frame identifier data is set by the data transmitting wireless terminal in the wireless data frame.
3. The data transferring method as claimed in claim 1, wherein the data transmitting wireless terminal invalidates the Ack request data when the wireless data frame is received.
4. A data transferring system comprising:
a data transmitting wireless terminal which validates an Acknowledgement (Ack) request data provided within a wireless data frame and transmits the wireless data frame; and
a data receiving wireless terminal which determines whether or not a frame identifier data indicating a sequence of each Ack request data provided in the wireless data frame received from the data transmitting wireless terminal is an expected one and whether or not a present Ack request data receiving interval is longer than a last Ack request data receiving interval, and decreases a redundant predetermined number of transmission frequency of each Ack data in response to each Ack request data only in case that the frame identifier data is found to be an expected one and the present Ack request data receiving interval is found to be longer than the last Ack request data receiving interval, or increases the redundant predetermined number of transmission frequency either in case that the frame identifier data is found to be an expected one or in case that the present Ack request data receiving interval is found to be not longer than the last Ack request data receiving interval while updating the Ack request data receiving interval to the present interval in either case;
the data transmitting wireless terminal extending or shortening a cycle for transmitting the Ack request data respectively depending on whether or not the Ack data in response to the Ack request data has been received within a fixed time during the cycle.
5. The data transferring system as claimed in claim 4, wherein only when the Ack request is valid the frame identifier data is set in the wireless data frame.
6. The data transferring system as claimed in claim 4, wherein the data transmitting wireless terminal invalidates the Ack request data when the wireless data frame is received.